Hepatitis B Vaccine

Heplisav hepatitis B vaccine shows efficacy in Phase II/III clinical trial

Published in Hepatitis Weekly, January 16th, 2006

Dynavax Technologies Corporation (DVAX) announced positive results from the primary endpoint analysis of the company's Phase II/III clinical trial comparing Heplisav, its hepatitis B virus (HBV) vaccine, with GlaxoSmithKline's Engerix-B vaccine.

Results showed superiority of Heplisav compared to Engerix-B relative to the primary efficacy endpoint of seroprotection (100% seroprotection in the Heplisav-treated group compared to 90.5% in the Engerix-B treated group; and relative to geometric mean concentration or GMC (1698 compared to 569 mIU/mL. Results also showed that subjects treated with Heplisav experienced more durable seroprotection. At week 50, the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry